Undervalued Drug Manufacturer Stocks on NYS March 2025

March 08, 2025

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

New York Stock Exchange

The New York Stock Exchange, located in New York City, is the largest securities exchange in the world by market capitalization of its listed companies.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
ELAN Elanco Animal Health 11.14 17.02 52.79 4920903 5540 0.00 16.4
RDY Dr Reddy's Laboratories 12.99 17.87 37.54 1847847 10838 0.74 17.5
OGN Organon 15.44 20.79 34.68 3475764 4001 7.25 4.6
BHC Bausch Health Companies 7.15 9.22 28.90 2627778 2631 0.00 0.0
ZTS Zoetis 167.25 204.91 22.52 3980318 76073 1.05 31.1
MRK Merck & Co 94.65 106.18 12.19 17528933 240506 3.30 14.0
BMY Bristol-Myers Squibb 61.09 63.46 3.88 12840116 123829 3.96 0.0
ABBV AbbVie 214.29 215.50 0.57 5698816 379936 2.94 89.7
All data provided as at market close March 06, 2025.

Company Details

Elanco Animal Health

ELAN:NYS

Close Price

11.14

Our Valuation

17.02

% Difference

52.79

Market Cap ($M)

5540

P/E Ratio

16.4

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries.

Access the stockcalc valuation


Dr Reddy's Laboratories

RDY:NYS

Close Price

12.99

Our Valuation

17.87

% Difference

37.54

Market Cap ($M)

10838

P/E Ratio

17.5

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr.

Access the stockcalc valuation


Organon

OGN:NYS

Close Price

15.44

Our Valuation

20.79

% Difference

34.68

Market Cap ($M)

4001

P/E Ratio

4.6

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan.

Access the stockcalc valuation


Bausch Health Companies

BHC:NYS

Close Price

7.15

Our Valuation

9.22

% Difference

28.90

Market Cap ($M)

2631

P/E Ratio

0.0

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Zoetis

ZTS:NYS

Close Price

167.25

Our Valuation

204.91

% Difference

22.52

Market Cap ($M)

76073

P/E Ratio

31.1

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals.

Access the stockcalc valuation


Merck & Co

MRK:NYS

Close Price

94.65

Our Valuation

106.18

% Difference

12.19

Market Cap ($M)

240506

P/E Ratio

14.0

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs.

Access the stockcalc valuation


Bristol-Myers Squibb

BMY:NYS

Close Price

61.09

Our Valuation

63.46

% Difference

3.88

Market Cap ($M)

123829

P/E Ratio

0.0

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Access the stockcalc valuation


AbbVie

ABBV:NYS

Close Price

214.29

Our Valuation

215.50

% Difference

0.57

Market Cap ($M)

379936

P/E Ratio

89.7

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Elanco Animal Health and Dr Reddy's Laboratories are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-march-2025
Elanco Animal Health $ELAN and Dr Reddy's Laboratories $RDY are the most undervalued Drug Manufacturers stocks on the #NYS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-march-2025
Elanco Animal Health and Dr Reddy's Laboratories are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-march-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.